One new challenge for vaccine design is the development of effective vaccines for the ever growing geriatric population. Influenza is a highly contagious viral infection of the respiratory tract that afflicts 3-5 million people world-wide with 200,000-500,000 deaths each year. The elderly (>65 years) are especially prone to severe influenza infection. There is now strong evidence that the seasonal H1N1 influenza vaccine is largely ineffective for these elderly subjects, subjecting them to high risk of complication, hospitalization and death. The ineffectiveness of current flu vaccines in the elderly has been associated with immunosenescence, which is a gradual age-associated deterioration of the immune system. There is growing belief that some of the key limitations resulting in immunosenescence can be overcome by improved immunization strategies, such as the use of novel adjuvants to promote effective memory immunity. Current adjuvants typically work by activating dendritic cells (DCs) at the site of vaccine administration and enhancing the trafficking of antigen-loaded DCs to the draining lymph nodes (DLNs), the epicenter of the adaptive immune response and where antigen presentation to T cells occurs. Here, we propose an alternate strategy to accelerate and maximize the immune responses. We recently developed a particle-mediated vaccine system capable of transporting critical immunostimulatory cytokines directly to the DLN during vaccination. This adjuvant technology induced rapid and significant organizational changes to the DLNs of aged mice, animals that are not immunoresponsive, like their human counterparts. The changes in the DLNs induced by targeted delivery of these immunomodulators were consistent with robust immune responses, including vigorous and sustained recruitment of not only DCs but also T cells. The objective of this proposal is to develop an effective immune stimulatory strategy and adjuvant formulation with the potential of overcoming immunosenescence.
The Specific aims are: 1) Optimize the composition, size and loading of biocompatible and degradable nanoparticles with various combinations of immunodulatory mediators to achieve maximal delivery and controlled release in the DLNs;2) Demonstrate the safety and efficacy of a vaccine formulation comprising the seasonal Flu vaccine and various cytokine-loaded nanoparticles in promoting maximal immunity in aged mice;3) Evaluate the prophylactic and therapeutic ability of the flu vaccine in combination with lymph node activating nanoparticles in protecting aged mice against lethal influenza virus infections. If proven successful, this approach could serve as a new paradigm for improving vaccines in general.

Public Health Relevance

to Healthcare Many vaccines are ineffective in elderly patients (>65 years) because of immunosenescence, a gradual age-associated deterioration of the immune system. We have developed a particle- mediated adjuvant technology capable of delivering critical immunostimulatory cytokines directly to the draining lymph node, the epicenter of the adaptive immune response and where antigen presentation to T cells occurs. By accelerating and maximizing the immune responses to previously non-responsive subpopulations, this vaccine technology may significantly improve the healthcare of elderly patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI096305-02
Application #
8414874
Study Section
Special Emphasis Panel (ZRG1-BST-T (02))
Program Officer
Salomon, Rachelle
Project Start
2012-02-01
Project End
2017-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
2
Fiscal Year
2013
Total Cost
$368,950
Indirect Cost
$133,950
Name
Duke University
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Karhausen, Jörn; Abraham, Soman N (2016) How mast cells make decisions. J Clin Invest 126:3735-3738
Chan, Hon Fai; Zhang, Ying; Leong, Kam W (2016) Efficient One-Step Production of Microencapsulated Hepatocyte Spheroids with Enhanced Functions. Small 12:2720-30
Miao, Yuxuan; Wu, Jianxuan; Abraham, Soman N (2016) Ubiquitination of Innate Immune Regulator TRAF3 Orchestrates Expulsion of Intracellular Bacteria by Exocyst Complex. Immunity 45:94-105
Choi, Hae Woong; Bowen, Samantha E; Miao, Yuxuan et al. (2016) Loss of Bladder Epithelium Induced by Cytolytic Mast Cell Granules. Immunity 45:1258-1269
Ji, HaYeun; Atchison, Leigh; Chen, Zaozao et al. (2016) Transdifferentiation of human endothelial progenitors into smooth muscle cells. Biomaterials 85:180-94
Choi, Hae Woong; Abraham, Soman N (2016) Why Serological Responses during Cystitis are Limited. Pathogens 5:
Ang, W X Gladys; Church, Alison M; Kulis, Mike et al. (2016) Mast cell desensitization inhibits calcium flux and aberrantly remodels actin. J Clin Invest 126:4103-4118
Chan, Hon Fai; Ma, Siying; Leong, Kam W (2016) Can microfluidics address biomanufacturing challenges in drug/gene/cell therapies? Regen Biomater 3:87-98
Jiang, Weiqian; Li, Mingqiang; Chen, Zaozao et al. (2016) Cell-laden microfluidic microgels for tissue regeneration. Lab Chip 16:4482-4506
Choi, Hae Woong; Abraham, Soman N (2015) Mast cell mediator responses and their suppression by pathogenic and commensal microorganisms. Mol Immunol 63:74-9

Showing the most recent 10 out of 43 publications